Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. has a strategic alliance with Orion Corporation to manufacture topical nitric oxide-releasing product candidates. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone919-485-8080
Debt
Current Ratio1.64
Quick Ratio1.64
Price-To-Earnings
Sales & Book Value
Annual Sales$2.14 million
Price / Sales16.44
Price / Cash FlowN/A
Price / Book-15.00
Profitability
Net Income$-37,120,000.00
Net Margins-1,087.54%
Return on Assets-82.50%
Miscellaneous
Employees59
OptionableNot Optionable
Novan (NASDAQ:NOVN) Frequently Asked Questions
What is Novan's stock symbol?
Novan trades on the NASDAQ under the ticker symbol "NOVN."
How were Novan's earnings last quarter?
Novan Inc (NASDAQ:NOVN) issued its quarterly earnings data on Monday, November, 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.32) by $0.05. The company had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.68 million. Novan had a negative net margin of 1,087.54% and a negative return on equity of 999.64%. View Novan's Earnings History.
When is Novan's next earnings date?
What price target have analysts set for NOVN?
3 brokers have issued 12 month price targets for Novan's stock. Their predictions range from $6.00 to $14.00. On average, they expect Novan's stock price to reach $8.6667 in the next year. This suggests a possible upside of 532.6% from the stock's current price. View Analyst Price Targets for Novan.
What is the consensus analysts' recommendation for Novan?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Novan.
What are Wall Street analysts saying about Novan stock?
Here are some recent quotes from research analysts about Novan stock:
- 1. According to Zacks Investment Research, "Novan, Inc. is a pharmaceutical company. It engaged in the development and commercialization of therapies using its nitric oxide platform for dermatology. The Company's product candidates primarily include SB204, SB206, SB208 and SB414 which are in pre-clinical trial stage. It develops product through Nitricil technology(TM). Novan, Inc. is based in Durham, United States. " (1/8/2019)
- 2. HC Wainwright analysts commented, "We eagerly anticipate, any day now, data from the Phase 2 dose-ranging study of SB206—topical nitric oxide (NO) gel—for molluscum contagiosum. We see molluscum as a large, underserved pediatric dermatology opportunity, with no FDA approved Rx treatments, and it is currently the key contributor to our Novan valuation. If Phase 2 is positive, with SB206 demonstrating meaningful molluscum lesion clearance rates at 12-weeks and good tolerability, it should be a transformational catalyst for Novan. Note that the only molluscum comparable, Verrica Pharmaceuticals (VRCA; not rated), which has positive open-label molluscum Phase 2 data and Phase 3 expected in 1Q19, has a $350M market cap—dramatically higher than Novan’s current $68M market cap." (11/6/2018)
Has Novan been receiving favorable news coverage?
News headlines about NOVN stock have trended positive this week, InfoTrie reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novan earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 7.0 out of 10, indicating that recent media coverage is likely to have an impact on the stock's share price in the near future.
Who are some of Novan's key competitors?
Some companies that are related to Novan include Galmed Pharmaceuticals (GLMD), Marinus Pharmaceuticals (MRNS), Imprimis Pharmaceuticals (IMMY), Axovant Sciences (AXON), Northwest Biotherapeutics (NWBO), BELLUS Health (BLUSF), Cue Biopharma (CUE), Processa Pharmaceuticals (PCSA), Proteostasis Therapeutics (PTI), Corvus Pharmaceuticals (CRVS), Chembio Diagnostics (CEMI), Adamis Pharmaceuticals (ADMP), Menlo Therapeutics (MNLO), XOMA (XOMA) and Avadel Pharmaceuticals (AVDL).
Who are Novan's key executives?
Novan's management team includes the folowing people:
- Mr. G. Kelly Martin, CEO & Director (Age 59)
- Dr. Nathan Stasko, Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)
- Mr. Jeff N. Hunter, Exec. VP, Chief Bus. Officer & Company Sec. (Age 61)
- Ms. Paula Brown Stafford, Chief Devel. Officer & Director (Age 53)
- Mr. Andrew J. Novak, VP & Chief Accounting Officer
When did Novan IPO?
(NOVN) raised $46 million in an initial public offering on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray acted as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
How do I buy shares of Novan?
Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novan's stock price today?
One share of NOVN stock can currently be purchased for approximately $1.37.
How big of a company is Novan?
Novan has a market capitalization of $33.87 million and generates $2.14 million in revenue each year. The company earns $-37,120,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Novan employs 59 workers across the globe.
What is Novan's official website?
How can I contact Novan?
Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]
MarketBeat Community Rating for Novan (NASDAQ NOVN)
MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
